INSILICO's stock price plummeted 7.90% during intraday trading on Friday, marking a significant decline for the biotechnology company.
The sharp drop followed the company's recent clarification that it currently has no definite plans for a second listing in Abu Dhabi. This announcement dashed market expectations that had anticipated such a move would broaden the company's international financing channels and deepen its strategic footprint in the Middle East region.
Additionally, with INSILICO having listed on the Hong Kong Stock Exchange in December last year, the company is now approaching the lock-up expiry window for certain early investors. This timing has raised market concerns about potential selling pressure from these investors, contributing to the negative sentiment surrounding the stock.
Comments